GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026

GT Biopharma, Inc.

2025-Q3 EPS reported -$1.84

Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.
Cash and equivalents $2.6M expected to fund operations into Q1 2026.
R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.
Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.
GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.